Atogepant

Generic Name: Atogepant

Brand Names: Qulipta, Aquipta

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₂₃F_₆N_₅O_₃

CAS Number: 1374248-81-3

Unique Ingredient Identifier: 7CRV8RR151

Background: Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. While its approval was predated by two other members of the same drug family, namely ubrogepant and rimegepant, th...

Indication: Atogepant is indicated for the preventive treatment of migraine in adults by the FDA, EMA, and Health Canada.

Associated Conditions: Episodic Migraine, Migraine

Associated Therapies: -

Clinical Trials

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Phase 3

Active, not recruiting

Conditions: Chronic Migraine

Interventions: Drug: Atogepant

First Posted Date: 2022-01-31

Last Posted Date: 2024-11-01

Lead Sponsor: AbbVie

Target Recruit Count: 75

Registration Number: NCT05216263

Locations: 🇺🇸
Michigan Headache & Neurological Institute (MHNI) /ID# 241784, Ann Arbor, Michigan, United States
🇺🇸
Minneapolis Clinic of Neurology - Burnsville /ID# 241994, Burnsville, Minnesota, United States
🇺🇸
Albany Medical College /ID# 242757, Albany, New York, United States

and more 26 locations

Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine

Phase 3

Completed

Conditions: Chronic Migraine

Interventions: Drug: Atogepant

First Posted Date: 2021-04-02

Last Posted Date: 2023-05-24

Lead Sponsor: Allergan

Target Recruit Count: 3

Registration Number: NCT04829747

Locations: 🇨🇳
Chinese PLA General Hospital /ID# 227546, Beijing, Beijing, China
🇨🇳
The Second Hospital of Shanxi Medical University /ID# 227567, Taiyuan, Shanxi, China
🇨🇳
The second Affiliated hospital of Zhejiang University school of Medicine /ID# 227558, Hangzhou, Zhejiang, China

Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

Phase 1

Completed

Conditions: Migraine

Interventions: Drug: Atogepant
Drug: Ubrogepant

First Posted Date: 2021-03-26

Last Posted Date: 2022-06-16

Lead Sponsor: AbbVie

Target Recruit Count: 26

Registration Number: NCT04818515

Locations: 🇺🇸
PPD Clinical Research Unit /ID# 227676, Orlando, Florida, United States
🇺🇸
Bio-Kinetic Clinical Applications, LLC /ID# 227675, Springfield, Missouri, United States
🇺🇸
Spaulding Clinical Research LLC /ID# 229505, West Bend, Wisconsin, United States

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Phase 3

Completed

Conditions: Episodic Migraine

Interventions: Drug: Atogepant

First Posted Date: 2019-05-06

Last Posted Date: 2022-05-12

Lead Sponsor: Allergan

Target Recruit Count: 685

Registration Number: NCT03939312

Locations: 🇺🇸
Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology, Atlanta, Georgia, United States
🇺🇸
Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States
🇺🇸
Neuro Pain Medical Center, Fresno, California, United States

and more 104 locations

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

Phase 3

Completed

Conditions: Episodic Migraine

Interventions: Drug: Placebo
Drug: Atogepant

First Posted Date: 2018-12-17

Last Posted Date: 2021-07-09

Lead Sponsor: Allergan

Target Recruit Count: 910

Registration Number: NCT03777059

Locations: 🇺🇸
Advanced Research Associates, Glendale, Arizona, United States
🇺🇸
Orange Grove Family Practice, Tucson, Arizona, United States
🇺🇸
Principals Research Group, Hot Springs, Arkansas, United States

and more 127 locations

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

Phase 3

Completed

Conditions: Episodic Migraine

Interventions: Drug: Standard of Care (SOC) Migraine Preventive Medication
Drug: Atogepant

First Posted Date: 2018-10-09

Last Posted Date: 2021-06-15

Lead Sponsor: Allergan

Target Recruit Count: 744

Registration Number: NCT03700320

Locations: 🇺🇸
iResearch Atlanta, Decatur, Georgia, United States
🇺🇸
FutureSearch Trials of Dallas, LP, Dallas, Texas, United States
🇺🇸
Rapid Medical Research, Inc., Cleveland, Ohio, United States

and more 98 locations

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

Phase 2

Completed

Conditions: Migraine, With or Without Aura

Interventions: Drug: Atogepant
Drug: Placebo-matching Atogepant

First Posted Date: 2016-07-28

Last Posted Date: 2018-12-06

Lead Sponsor: Allergan

Target Recruit Count: 834

Registration Number: NCT02848326

Locations: 🇺🇸
Central Texas Neurology Consultant, Round Rock, Texas, United States
🇺🇸
Irvine Center for Clinical Research, Irvine, California, United States
🇺🇸
iResearch Atlanta, LLC, Decatur, Georgia, United States

and more 70 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy